Current Insights and Management of Merkel Cell Carcinoma

The presentation on Merkel Cell Carcinoma (MCC) encompasses an overview of its clinical features, pathophysiology, and current diagnostic and management strategies. MCC typically arises on UV-exposed skin and presents as rapidly growing nodules that are often misdiagnosed due to their nonspecific appearance. Between 60-80% of cases are linked to the Merkel cell polyomavirus, with differing mutational profiles affecting prognosis. Despite a generally poor prognosis across all stages (with five-year survival rates ranging from 62% for stage 1 to 13.5% for advanced stages), recent findings indicate that patients with early-stage disease often fare better than previously suggested, giving rise to optimism in management outcomes. Imaging, particularly PET scans, is commonly used for detecting occult metastases, while the role of brain MRIs has been reduced due to the low incidence of intracranial metastases. Lymph node evaluations are vital, and sentinel lymph node biopsies are recommended even in the absence of observable disease on scans. Novel blood tests, such as the Merkel Cell Viral Antibody test, have shown promise for assessing prognosis and recurrence risk. The potential utility of circulating tumor DNA (ctDNA) is also being explored for monitoring disease progression. Immunotherapy has emerged as a pivotal treatment modality, indicating robust response rates when employed as frontline therapy. Ongoing clinical trials are assessing neoadjuvant and adjuvant immunotherapy approaches, indicating significant advancements in managing this aggressive skin cancer.